Michael S. Brown - 29 Mar 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: Director
Signature: /s/**Michael S. Brown
Issuer symbol: REGN
Transactions as of: 29 Mar 2022
Net transactions value: -$627,018
Form type: 4
Filing time: 31 Mar 2022, 16:04:48 UTC
Previous filing: 24 Feb 2022
Next filing: 10 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$569,411	+1,522	+141%	$374.12	2,604	29 Mar 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$1,063,878	-1,522	-58%	$699.00	1,082	29 Mar 2022	Direct	F1
transaction	REGN	Common Stock	Options Exercise	$152,641	+408	+38%	$374.12	1,490	30 Mar 2022	Direct	F1
transaction	REGN	Common Stock	Sale	$285,192	-408	-27%	$699.00	1,082	30 Mar 2022	Direct	F1
holding	REGN	Common Stock						5,000	29 Mar 2022	by SLAT	F2
holding	REGN	Common Stock						7,162	29 Mar 2022	by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-1,522	-35%	$0.000000	2,839	29 Mar 2022	Common Stock	1,522	$374.12	Direct	F1, F3
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-408	-14%	$0.000000	2,431	30 Mar 2022	Common Stock	408	$374.12	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2	These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3	On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.